PMID- 16436143
OWN - NLM
STAT- MEDLINE
DCOM- 20060707
LR  - 20061115
IS  - 0105-4538 (Print)
IS  - 0105-4538 (Linking)
VI  - 61
IP  - 3
DP  - 2006 Mar
TI  - ImmunoCAP Phadiatop Infant--a new blood test for detecting IgE sensitisation in 
      children at 2 years of age.
PG  - 337-43
AB  - BACKGROUND: Correct diagnosis of immunoglobulin E (IgE)-mediated disease is the 
      prerequisite for secondary allergy prevention during early childhood. OBJECTIVE: 
      To evaluate the diagnostic efficacy of a new blood test, Phadiatop Infant, in 
      detecting IgE sensitisation to food and inhalant allergens among children at 2 
      years of age. METHODS: Children (n = 239) were followed prospectively from birth 
      to 2 years of age for the presence of IgE sensitisation and the development of 
      atopic manifestations. Immunoglobulin E sensitisation was evaluated by skin prick 
      test (SPT) and analysis of allergen-specific IgE antibodies in plasma to food and 
      inhalant allergens. The children were classified into three groups: 
      IgE-sensitised, non-IgE sensitised and inconclusive, depending on SPT and 
      allergen-specific IgE results. RESULTS: Twenty-six (11%) of the children were 
      classified as IgE-sensitised, 182 (76%) as non-IgE sensitised and 31 (13%) as 
      inconclusive. Phadiatop Infant was positive in 50 (21%) of the children. Ten 
      children (4%) with identified IgE antibodies against the selected food and 
      inhalant allergens showed negative Phadiatop Infant. Three children showed 
      positive Phadiatop Infant but were negative in the other tests performed. These 
      results correspond to positive and negative predictive values for Phadiatop 
      Infant of 89 and 99%, respectively. Children with clinical symptoms of atopic 
      diseases had significantly increased levels for Phadiatop Infant (P < 0.01). 
      CONCLUSION: Phadiatop Infant appears to be a reliable alternative to SPT and the 
      measurement of allergen-specific IgE antibodies in plasma for detecting 
      clinically important IgE sensitisation among children at 2 years of age.
FAU - Ballardini, N
AU  - Ballardini N
AD  - Sachs' Children's Hospital, South Hospital, Karolinska Institutet, Stockholm, 
      Sweden.
FAU - Nilsson, C
AU  - Nilsson C
FAU - Nilsson, M
AU  - Nilsson M
FAU - Lilja, G
AU  - Lilja G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Age Factors
MH  - Allergens/adverse effects/immunology
MH  - Antibodies, Anti-Idiotypic/*blood
MH  - Child, Preschool
MH  - Confidence Intervals
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypersensitivity, Immediate/blood/*diagnosis/epidemiology
MH  - Immunization
MH  - Immunoglobulin E/*immunology
MH  - Immunologic Tests/methods
MH  - Incidence
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Odds Ratio
MH  - Prospective Studies
MH  - ROC Curve
MH  - Risk Assessment
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Skin Tests/*methods
MH  - Statistics, Nonparametric
EDAT- 2006/01/27 09:00
MHDA- 2006/07/11 09:00
CRDT- 2006/01/27 09:00
PHST- 2006/01/27 09:00 [pubmed]
PHST- 2006/07/11 09:00 [medline]
PHST- 2006/01/27 09:00 [entrez]
AID - ALL936 [pii]
AID - 10.1111/j.1398-9995.2005.00936.x [doi]
PST - ppublish
SO  - Allergy. 2006 Mar;61(3):337-43. doi: 10.1111/j.1398-9995.2005.00936.x.